D-0127-2018 Class III Terminated

Recalled by Claris Lifesciences Inc — North Brunswick, NJ

FDA drug recall D-0127-2018 was initiated by Claris Lifesciences Inc on Nov 6, 2017 and is designated Class III. Reason for recall: Superpotent The recall status is terminated (terminated Apr 20, 2020).

Recall details

Product Type
Drugs
Report Date
Dec 27, 2017
Initiation Date
Nov 6, 2017
Termination Date
Apr 20, 2020
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Ciprofloxacin in Dextrose (5%) Injection, USP 200 mg in 100 mL 5% Dextrose, Rx Only, (2 mg/mL), 100 mL Flexible Bag, Manufactured for: Claris LifeScience Inc. North Brunswick NJ 08902 by Claris Injectables Ltd. Gujarat, India UPC 336000008242 NDC 36000-008-249

Reason for recall

Superpotent

Distribution pattern

Nationwide

Code information

A060192 01/2018; A060305 02/2018; A061038 08/2018; A0A0068 12/2018; A0A0404 04/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0127-2018
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0127-2018. Report a data issue: hello@regdatalab.com.